Forecasts Impressive CAGR 15.4%and Multimillion-Dollar Value for US$ 2644.94 million Short Bowel Syndrome Market by 2030

Comments · 157 Views

nikita gawade 18 Jul 2023

Short Bowel Syndrome Market, By Drug Type (Anti-Diarrheals, Proton Pump Inhibitors, Histamine Blockers, Growth Hormone, Glucagon-like Peptide, and Others), By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, and Others), and By Region (North America, Latin America, Europe,

Sample link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/137

Key Development:

· In April 2021, Hanmi Pharm. Co. Ltd. announced that the U.S. Food and Drug Administration had granted fast-track designation to its short-bowel syndrome therapy, LAPS GLP-2 Analog (HM15912).

In June 2021, VectivBio Holding AG announced that the FDA had granted orphan drug designation to Apraglutide, a next-generation, long-acting GLP-2 analog being developed for rare gastrointestinal (GI) diseases, for the prevention of acute graft-versus-host disease (aGVHDc).

#Short Bowel Syndrome Market trends